Every material Form 8-K Axsome Therapeutics, Inc. has filed with the SEC since July 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Axsome Therapeutics reported third quarter 2026 total revenue of $259.7 million, up 52% from $171.0 million a year earlier, and a net loss of $12.9 million, or $(0.25) per share, versus $47.2 million, or $(0.94) per share, in the prior-year quarter. Operating costs rose, with SG&A expenses of $203.1 million compared with $150.2 million, and the company said its current cash is sufficient to fund operations into cash flow positivity.
Total revenue was $259.7 million for Q3 2026, versus $171.0 million in Q3 2025; AUVELITY net product sales were $207.6 million, up 53%.
Net loss narrowed to $12.9 million, or $(0.25) per share, from $47.2 million, or $(0.94) per share; the loss includes $26.4 million in stock-based compensation.
SG&A expenses rose to $203.1 million from $150.2 million, and R&D expenses rose to $50.6 million from $40.2 million.
Cash and cash equivalents were $313.9 million at September 30, 2026, compared with $322.9 million at December 31, 2025.
Axsome reported second-quarter 2026 total net product revenue of $218.4 million, up 46% year over year, with AUVELITY contributing $180.3 million. The net loss widened to $51.3 million, or $(0.99) per share, from $48.0 million, or $(0.97) per share, a year earlier, as selling, general and administrative expenses rose to $208.1 million. Revenue growth and the larger loss point in opposite directions for shareholders.
Total net product revenue was $218.4 million, up from $150.0 million; AUVELITY net product sales were $180.3 million, up 51%.
Net loss was $51.3 million, or $(0.99) per share, versus $48.0 million, or $(0.97) per share, in the second quarter of 2025.
SG&A expenses rose to $208.1 million from $130.3 million, primarily reflecting AUVELITY commercialization, including the sales force expansion and Alzheimer's disease agitation launch.
Cash and cash equivalents totaled $319.9 million at June 30, 2026; the company believes this is sufficient to fund operations into cash flow positivity.
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 is not approved by the FDA, and the filing contains no financial results.
FDA accepted the New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy for filing
PDUFA target action date set for May 1, 2027
FDA does not currently plan to hold an advisory committee meeting
AXS-12 has FDA Orphan Drug Designation for the treatment of narcolepsy
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Axsome Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →